Abstract

Objectives: The COVID-19 pandemic has rapidly become a global health crisis. Currently, there are no proven, reliable, specific treatments for COVID-19. Alongside drug interventions, supportive treatments are implemented during the disease. Quercetin, recognized for its antiviral, anti-inflammatory, anti-aging, and antioxidant properties, is under evaluation in this study for its potential impact on preventing, influencing the course, and mitigating the severity of COVID-19.

Methods: A thorough search was conducted across scientific databases, including PubMed, Embase, Web of Science, SAGEpub, Copernicus, Cochrane Library, ScienceDirect, Elsevier, Scopus, Google Scholar, EBSCOhost, Crossref, Ovid-LWW, and DergiPark databases, between 1 November 2021 and 1 April 2022 to ensure a comprehensive inclusion of relevant studies.

Results: Thirteen randomized controlled clinical trials (five published, eight unpublished) were identified. Existing literature supports quercetin’s role as a potent free radical scavenger with robust antioxidant properties. It exhibits anti-inflammatory characteristics by inhibiting lipid peroxidation and restraining pro-inflammatory enzymes such as lipoxygenase and phospholipase A2. Scholarly discourse suggests that quercetin supplementation within the 500-1500 mg range leads to favorable outcomes, including quicker patient discharge, reduced inflammation, increased respiratory rate, accelerated viral clearance, and an improved disease prognosis. However, it is noted that intervention durations vary across studies.

Conclusions: The analysis of the studies suggested that quercetin is a promising therapeutic agent that can cause a decrease in disease symptoms, frequency of hospitalization, hospital stay, need for non-invasive oxygen treatment, need for intensive care, and mortality. Nonetheless, more clinical studies are needed to better understand quercetin’s curative effects on COVID-19 infection.

Keywords: Quercetin, COVID-19, randomized controlled trials

Copyright and license

Copyright © 2024 The author(s). This is an open-access article under the terms of the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

How to cite

1.
Beşler ZN, Bayraktar DZ, Koçak MC, Kızıltan G. Investigation of potential effects of quercetin on COVID-19 treatment: a systematic review of randomized controlled trials. Clin Sci Nutr. 2024;6(2):107-117. doi:10.62210/ClinSciNutr.2024.86

References

  1. T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü. COVID-19 (SARS-CoV-2 Enfeksiyonu) Genel Bilgiler, Epidemiyoloji ve Tanı [COVID-19 (SARS-CoV-2 Infection) General Information, Epidemiology and Diagnosis]. Ankara; 2020.
  2. World Health Organization (WHO). WHO Coronavirus Disease (COVID-19) Dashboard with Vaccination Data. Available at: https://data.who.int/dashboards/covid19/cases?n=c (Accessed on March 17, 2024).
  3. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus 2019 (COVID-19): A review. JAMA. 2020;324:782-793. https://doi.org/10.1001/jama.2020.12839
  4. T.C. Sağlık Bakanlığı. COVID-19 (SARS-CoV-2 Enfeksiyonu) Erişkin Hasta Tedavisi. 2022.
  5. Karaağaç Y, Bellikci Koyu E. Vitamins and minerals in viral infections: a review focusing on COVID-19. İzmir Katip Çelebi University Faculty of Health Science Journal. 2020;5:165-173.
  6. Kaul R, Paul P, Kumar S, Büsselberg D, Dwivedi VD, Chaari A. Promising antiviral activities of natural flavonoids against SARS-CoV-2 targets: Systematic review. Int J Mol Sci. 2021;22:11069. https://doi.org/10.3390/ijms222011069
  7. Di Pierro F, Derosa G, Maffioli P, et al. Possible Therapeutic effects of adjuvant quercetin supplementation against early-stage COVID-19 Infection: A prospective, randomized, controlled, and open-label study. Int J Gen Med. 2021;14:2359-2366. https://doi.org/10.2147/IJGM.S318720
  8. Bastaminejad S, Bakhtiyari S. Quercetin and its relative therapeutic potential against COVID-19: A retrospective review and prospective overview. Curr Mol Med. 2021;21:385-391. https://doi.org/10.2174/1566524020999200918150630
  9. Bernini R, Velotti F. Natural polyphenols as immunomodulators to rescue immune response homeostasis: Quercetin as a research model against severe COVID-19. Molecules. 2021;26:5803. https://doi.org/10.3390/molecules26195803
  10. Derosa G, Maffioli P, D'Angelo A, Di Pierro F. A role for quercetin in coronavirus disease 2019 (COVID-19). Phytother Res. 2021;35:1230-1236. https://doi.org/10.1002/ptr.6887
  11. Magar RT, Sohng JK. A Review on structure, modifications and structure-activity relation of quercetin and its derivatives. J Microbiol Biotechnol. 2020;30:11-20. https://doi.org/10.4014/jmb.1907.07003
  12. Zou H, Ye H, Kamaraj R, Zhang T, Zhang J, Pavek P. A review on pharmacological activities and synergistic effect of quercetin with small molecule agents. Phytomedicine. 2021;92:153736. https://doi.org/10.1016/j.phymed.2021.153736
  13. Jakaria M, Azam S, Jo SH, Kim IS, Dash R, Choi DK. Potential therapeutic targets of quercetin and its derivatives: Its role in the therapy of cognitive impairment. J Clin Med. 2019;8:1789. https://doi.org/10.3390/jcm8111789
  14. Ahmed AK, Albalawi YS, Shora HA, Abdelseed HK, Al-Kattan AN. Effects of quadruple therapy: Zinc, quercetin, bromelain and vitamin C on the clinical outcomes of patients infected with COVID-19. Res Int J Endocrinol Diabetes. 2020;1(1):018-021. https://doi.org/10.37179/rijed.000005
  15. Margolin L, Luchins J, Margolin D, Margolin M, Lefkowitz S. 20-week study of clinical outcomes of over-the-counter COVID-19 prophylaxis and treatment. J Evid Based Integr Med. 2021;26:2515690X211026193. https://doi.org/10.1177/2515690X211026193
  16. Schettig R, Sears T, Klein M, et al. COVID-19 patient with multifocal pneumonia and respiratory difficulty resolved quickly: possible antiviral and anti-inflammatory benefits of quercinex (Nebulized Quercetin-NAC) as adjuvant. Adv Infect Dis. 2020;10:45-55. https://doi.org/10.4236/aid.2020.103006
  17. Kamel A, Abdelseed H, Albalawi Y, Aslsalameen E, Almutairi Y, Alkattan A. Evaluation of the effect of zinc, quercetin, bromelain and vitamin C on COVID-19 patients. MedRxiv [Preprint]. https://doi.org/10.1101/2020.12.22.20245993
  18. Shohan M, Nashibi R, Mahmoudian-Sani MR, et al. The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial. Eur J Pharmacol. 2022;914:174615. https://doi.org/10.1016/j.ejphar.2021.174615
  19. Ali S, Alam M, Khatoon F, et al. Natural products can be used in therapeutic management of COVID-19: Probable mechanistic insights. Biomed Pharmacother. 2022;147:112658. https://doi.org/10.1016/j.biopha.2022.112658
  20. Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160. https://doi.org/10.1136/bmj.n160
  21. Covidence. Cochrane Community. Available at: https://community.cochrane.org/help/tools-and-software/COVIDence (Accessed on Apr 15, 2022).
  22. Di Pierro F, Iqtadar S, Khan A, et al. Potential clinical benefits of quercetin in the early stage of COVID-19: Results of a second, pilot, randomized, controlled and open-label clinical trial. Int J Gen Med. 2021;14:2807-2816. https://doi.org/10.2147/IJGM.S318949
  23. Rondanelli M, Perna S, Gasparri C, et al. Promising effects of 3-month period of quercetin Phytosome® supplementation in the prevention of symptomatic COVID-19 disease in healthcare workers: A pilot study. Life (Basel). 2022;12:66. https://doi.org/10.3390/life12010066
  24. Önal H, Arslan B, Üçüncü Ergun N, et al. Treatment of COVID-19 patients with quercetin: A prospective, single center, randomized, controlled trial. Turk J Biol. 2021;45:518-529. https://doi.org/10.3906/biy-2104-16
  25. Xu D, Hu MJ, Wang YQ, Cui YL. Antioxidant activities of quercetin and its complexes for medicinal application. Molecules. 2019;24:1123. https://doi.org/10.3390/molecules24061123
  26. Ullah A, Munir S, Badshah SL, et al. Important flavonoids and their role as a therapeutic agent. Molecules. 2020;25:5243. https://doi.org/10.3390/molecules25225243
  27. Li Y, Yao J, Han C, et al. Quercetin, inflammation and immunity. Nutrients. 2016;8:167. https://doi.org/10.3390/nu8030167
  28. Moradian N, Gouravani M, Salehi MA, et al. Cytokine release syndrome: inhibition of pro-inflammatory cytokines as a solution for reducing COVID-19 mortality. Eur Cytokine Netw. 2020;31:81-93. https://doi.org/10.1684/ecn.2020.0451
  29. Chen W, Zheng KI, Liu S, Yan Z, Xu C, Qiao Z. Plasma CRP level is positively associated with the severity of COVID-19. Ann Clin Microbiol Antimicrob. 2020;19:18. https://doi.org/10.1186/s12941-020-00362-2
  30. Gasmi A, Mujawdiya PK, Lysiuk R, et al. Quercetin in the prevention and treatment of coronavirus infections: A focus on SARS-CoV-2. Pharmaceuticals (Basel). 2022;15:1049. https://doi.org/10.3390/ph15091049
  31. Zwicker JI, Schlechter BL, Stopa JD, et al. Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. JCI Insight. 2019;4:e125851. https://doi.org/10.1172/jci.insight.125851
  32. Riva A, Ronchi M, Petrangolini G, Bosisio S, Allegrini P. Improved oral absorption of quercetin from quercetin Phytosome®, a new delivery system based on food grade lecithin. Eur J Drug Metab Pharmacokinet. 2019;44:169-177. https://doi.org/10.1007/s13318-018-0517-3
  33. Karataş A, Turhan F. Phyto-phospholipid complexes as drug delivery system for herbal extracts/molecules. Artic Turkish J Pharm Sci. 2015;12(1):93-102.
  34. Riva A, Corti A, Belcaro G, et al. Interaction study between antiplatelet agents, anticoagulants, diabetic therapy and a novel delivery form of quercetin. Minerva Cardioangiol. 2019;67:79-83. https://doi.org/10.23736/S0026-4725.18.04795-3
  35. Di Pede G, Bresciani L, Calani L, et al. The human microbial metabolism of quercetin in different formulations: An in vitro evaluation. Foods. 2020;9:1121. https://doi.org/10.3390/foods9081121
  36. Zhao N, Di B, Xu LL. The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies. Cytokine Growth Factor Rev. 2021;61:2-15. https://doi.org/10.1016/j.cytogfr.2021.06.002
  37. Glinsky GV. Tripartite combination of candidate pandemic mitigation agents: vitamin d, quercetin, and estradiol manifest properties of medicinal agents for targeted mitigation of the COVID-19 pandemic defined by genomics-guided tracing of SARS-CoV-2 targets in human cells. Biomedicines. 2020;8:129. https://doi.org/10.3390/biomedicines8050129
  38. Al Shukor N, Van Camp J, Gonzales GB, et al. Angiotensin-converting enzyme inhibitory effects by plant phenolic compounds: a study of structure activity relationships. J Agric Food Chem. 2013;61:11832-11839. https://doi.org/10.1021/jf404641v
  39. Marín-Corral J, Rodríguez-Morató J, Gomez-Gomez A, et al. Metabolic signatures associated with severity in hospitalized COVID-19 patients. Int J Mol Sci. 2021;22:4794. https://doi.org/10.3390/ijms22094794
  40. Carpinteiro A, Edwards MJ, Hoffmann M, et al. Pharmacological inhibition of acid sphingomyelinase prevents uptake of SARS-CoV-2 by epithelial cells. Cell Rep Med. 2020;1:100142. https://doi.org/10.1016/j.xcrm.2020.100142
  41. Chamorro V, Pandolfi R, Moreno L, et al. Effects of quercetin in a rat model of hemorrhagic traumatic shock and reperfusion. Molecules. 2016;21:1739. https://doi.org/10.3390/molecules21121739
  42. Jo S, Kim S, Shin DH, Kim MS. Inhibition of SARS-CoV 3CL protease by flavonoids. J Enzyme Inhib Med Chem. 2020;35:145-151. https://doi.org/10.1080/14756366.2019.1690480
  43. Pawar A, Russo M, Rani I, Goswami K, Russo GL, Pal A. A critical evaluation of risk to reward ratio of quercetin supplementation for COVID-19 and associated comorbid conditions. Phytother Res. 2022;36:2394-2415. https://doi.org/10.1002/ptr.7461
  44. Colunga Biancatelli RML, Berrill M, Catravas JD, Marik PE. Quercetin and vitamin c: an experimental, synergistic therapy for the prevention and treatment of SARS-CoV-2 related disease (COVID-19). Front Immunol. 2020;11:1451. https://doi.org/10.3389/fimmu.2020.01451
  45. Dabbagh-Bazarbachi H, Clergeaud G, Quesada IM, Ortiz M, O'Sullivan CK, Fernández-Larrea JB. Zinc ionophore activity of quercetin and epigallocatechin-gallate: from Hepa 1-6 cells to a liposome model. J Agric Food Chem. 2014;62:8085-8093. https://doi.org/10.1021/jf5014633
  46. Cancio M, Ciccocioppo R, Rocco PR, et al. Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies. Cytotherapy. 2020;22:474-481. https://doi.org/10.1016/j.jcyt.2020.04.100
  47. Kuznetsova T, Prange KHM, Glass CK, de Winther MPJ. Transcriptional and epigenetic regulation of macrophages in atherosclerosis. Nat Rev Cardiol. 2020;17:216-228. https://doi.org/10.1038/s41569-019-0265-3
  48. Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVID-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34:327-331.
  49. Mendes LF, Gaspar VM, Conde TA, Mano JF, Duarte IF. Flavonoid-mediated immunomodulation of human macrophages involves key metabolites and metabolic pathways. Sci Rep. 2019;9:14906. https://doi.org/10.1038/s41598-019-51113-z
  50. Arslan B, Ucuncu Ergun N, Topuz S, et al. Synergistic effect of quercetin and vitamin C against COVID-19: Is a possible guard for front liners. SSRN Electron J. 2020. https://doi.org/10.2139/ssrn.3682517
  51. Lee S, Yu Y, Trimpert J, et al. Virus-induced senescence is a driver and therapeutic target in COVID-19. Nature. 2021;599:283-289. https://doi.org/10.1038/s41586-021-03995-1